MedPath

Investigations of the changes in overactive bladder symptoms after the discontinuation of drug for overactive bladder in benign prostatic hyperplasia patients with coexisting overactive bladder

Not Applicable
Completed
Conditions
Diseases of The genitoruinary system
Registration Number
KCT0000392
Lead Sponsor
Kangwon National University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
120
Inclusion Criteria

Elligible patients are men 45 years or older with a total International Prostate Symptom Score (IPSS) of 8 or higher, a total overactive bladder symptoms score (OABSS) of 3 or higher and a score of 3rd item (urgency) of the OABSS of at least 2, and findings suggestive of BPH on transrectal ultrasonography.

Exclusion Criteria

Those with acute urinary tract infection, significant renal dysfunction, significant hepatic dysfunction, a history of stroke or Parkinsonism, or a history of prostate cancer or PSA of 10ng/ml or more will be excluded.
And those with postvoid residual urine (PVR) more than 100ml, or maximum flow rate less than 8ml/s will be excluded

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OABSS (overactive bladder symptoms score);PPBC (the patient perception of bladder condition);storage symptom score of IPSS (international prostate symptom score);QOL score
Secondary Outcome Measures
NameTimeMethod
total micturitions per 24 hours on frequency-volume chart;micturitions per night on frequency-volume chart;functional bladder capacity on frequency-volume chart;voiding symptom score of IPSS;maximum flow rate on uroflowmetyr;postvoid residual urine;patients' intention of resuming administration of solifenacin;adverse events
© Copyright 2025. All Rights Reserved by MedPath